# Selecxine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/selecxine

- Industry: Biotechnology
- Headquarters: Pohang, South Korea
- Website: www.selecxine.com
- Total disclosed funding: $38M
- Latest round: Series B (Mar 29, 2022)
- Investors on record: 16

## About

Based in Pohang, South Korea, and founded in 2018, Selecxine operates as a biopharmaceutical development company that develops anti-cancer immunotherapeutics. In 2018, the company was awarded the Innovative Technology Support Award by the Ministry of SMEs and Startups. In 2019, the company developed TCB2 technology, an anti-human interleukin-2 antibody agent. In 2020, Selecxine was again selected as one of the most outstanding companies by the Ministry of SMEs and Startups. In May 2020, Selecxine raised KRW 13.7 billion in series A funding from new investors BM Ventures, Hanwha Investment & Securities, K-Run Ventures, Lighthouse Combined Investment, Medytox Venture Investment, POSCO Capital, Quantum Ventures Korea, SJ Investment Partners, and Stonebridge Ventures. In 2021, the company registered a TCB2 patent filing in the USA, Australia, and Russia. The current CEO of the company is Jun-Young Lee.

Selecxine develops antibody platform technology for anti-cancer immunotherapeutics. Its main platform technology is SLC-3010, which is an immune-mediated anti-cancer therapeutics for anti-human IL-2 antibody (TCB2).

## Funding rounds

- Series B, Mar 29, 2022, $27M — Hyundai Venture Investment, UTC Investment, SJ Investment Partners, Medici Investment, STIC Ventures, Hanwha Investment & Securities, Medytox Venture Investment, Stonebridge Ventures, KClavis Investment, iM Investment Partners
- Series A, May 7, 2020, $11M — IMM Investment, Posco Investment, SJ Investment Partners, K-Run Ventures, Quantum Ventures Korea, Lighthouse Combined Investment, Hanwha Investment & Securities, Medytox Venture Investment, Stonebridge Ventures, BM Ventures

## Investors

- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series A
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A, Series B
- K-Run Ventures (https://capitalatlas.ai/funds/k-run-ventures) — Series A
- Quantum Ventures Korea (https://capitalatlas.ai/funds/quantum-ventures-korea) — Series A
- Lighthouse Combined Investment (https://capitalatlas.ai/funds/lighthouse-combined-investment) — Series A
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series A, Series B
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A, Series B
- Stonebridge Ventures — Series A, Series B
- BM Ventures (https://capitalatlas.ai/funds/bm-ventures) — Series A
- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series B
- iM Investment Partners (https://capitalatlas.ai/funds/im-investment-partners) — Series B